Pharmacology

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

4. Mai 2026 Von KI berichtet

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Researchers at Adelaide University report that salcaprozate sodium (SNAC)—an absorption enhancer used in oral semaglutide tablets—was associated with changes in gut bacteria and inflammation markers in an animal study conducted over 21 days. The authors said the findings do not demonstrate harm in humans but argue that longer-term research is needed as oral options for obesity treatment expand.

27. Februar 2026 Von KI berichtet

Scientists at Nagoya University have developed an iron-based photocatalyst that reduces reliance on rare metals in organic synthesis. The new design uses fewer costly chiral ligands and enables the first asymmetric total synthesis of (+)-heitziamide A. This advance promotes more sustainable chemical reactions under blue LED light.

New research indicates that regular use of ibuprofen, a common painkiller, may reduce the risk of endometrial cancer by up to 25% in certain women. This finding comes from a large-scale study analyzing over 42,000 participants, highlighting the drug's anti-inflammatory properties. However, experts caution against using it for prevention due to potential side effects.

16. Januar 2026 Von KI berichtet

Researchers have discovered that a byproduct of vitamin A, all-trans retinoic acid, weakens the immune system's fight against cancer and reduces the effectiveness of certain vaccines. In preclinical studies, a new drug called KyA33 blocks this pathway, enhancing immune responses and slowing tumor growth. The findings, from two studies, explain a long-standing paradox about vitamin A's role in cancer.